Anxiety disorders are the most common mental health diagnoses in the United States, affecting approximately 40 million adults, yet a substantial portion of those patients do not achieve adequate relief with standard first-line treatments such as SSRIs, SNRIs, and cognitive behavioral therapy. The limitations of these approaches — particularly their slow onset, partial efficacy, and the significant burden of side effects that lead many patients to discontinue — have prompted serious clinical and research interest in ketamine as a potential option for treatment-resistant anxiety. At Minnesota Ketamine & Wellness Institute, we work with patients managing a range of anxiety presentations, and we want to share what the evidence currently supports along with what we observe in clinical practice.
The Neuroscience Behind Ketamine and Anxiety
Anxiety disorders encompass several distinct diagnoses — generalized anxiety disorder, social anxiety disorder, panic disorder, specific phobias, and separation anxiety among them — and they vary considerably in their neurobiology, symptom profile, and treatment responsiveness. What links many of these presentations is a hyperactive threat-detection system, a nervous system that signals danger in contexts where it is not proportionate to actual risk. The amygdala, the brain region most associated with fear processing, plays a central role, as does the balance between excitatory glutamate signaling and inhibitory GABA signaling. Chronic anxiety appears to involve dysregulation of both systems, and ketamine’s mechanism — acting primarily on NMDA glutamate receptors — positions it as a pharmacologically logical candidate for anxiety treatment. For a deeper look at this mechanism, see our Ketamine Dictionary entry on the NMDA receptor.
The research base for ketamine in anxiety is less developed than the literature on depression and PTSD, but it is growing. Studies published in peer-reviewed journals including Neuropsychopharmacology and the Journal of Psychopharmacology have reported rapid reductions in anxiety symptoms following ketamine administration, with some patients experiencing relief within hours of the first session. Research from Yale University’s mood disorders program — one of the early institutional leaders in ketamine research — has examined the relationship between ketamine’s anti-anhedonic and anxiolytic effects and proposed mechanisms involving both AMPA receptor potentiation and BDNF-mTOR signaling. Importantly, the psychiatric use of IV ketamine for anxiety is off-label — it has not received FDA approval for this indication — and we communicate that clearly with every patient during intake.
What We See Clinically
What we observe clinically at our institute aligns with the emerging research, with the important caveat that individual responses vary considerably. Some patients with significant anxiety histories report a notable reduction in baseline tension and rumination after the initial infusion series. Others see their anxiety symptoms shift more slowly, sometimes requiring integration work to address the underlying cognitive and somatic patterns that ketamine begins to loosen but does not resolve on its own. This is why we place such emphasis on the ketamine-assisted psychotherapy model — the neuroplastic window opened by ketamine is most useful when a skilled clinician accompanies the patient in working through what surfaces. Our therapists include Somatic Psychedelic Facilitators and Certified Clinical Trauma Professionals who are specifically trained to work with anxiety presentations in non-ordinary states.
Addressing the Fear of the Experience Itself
One barrier that consistently comes up among anxiety patients considering ketamine is the anxiety about the ketamine experience itself. The prospect of entering a dissociative state — losing ordinary sensory reference points, experiencing perceptual changes, feeling temporarily disconnected from familiar thought patterns — can be genuinely frightening for someone whose core distress is already a loss of felt safety. We take this concern very seriously. Our preparation protocol for anxiety patients places particular emphasis on developing a clear sense of safety in the therapeutic relationship before the first session. We walk through exactly what to expect, how our clinical team will be present throughout, and how to use grounding techniques if the experience feels overwhelming. Christy Hatcher’s CRNA background means patients have a provider with deep pharmacological knowledge managing the infusion itself — someone who understands dosing, timing, and the physiological parameters of the session with precision. If you want to understand what the experience is like firsthand, our post on what ketamine therapy feels like offers a detailed, patient-centered overview. Discuss with your provider in detail how your anxiety history informs the preparation approach before your first session.
Cost, Insurance, and Access Pathways
Cost and insurance remain real obstacles for anxiety patients specifically. Because IV ketamine for anxiety is off-label, insurance coverage is unlikely through most commercial plans, and the out-of-pocket investment is meaningful. We encourage prospective patients to have a clear conversation with our team about what treatment actually involves financially so that anxiety about cost does not compound the clinical anxiety they are already managing. For a full breakdown of what to expect financially, our guide to ketamine therapy cost in Minnesota is a useful starting point.
For patients whose anxiety coexists with treatment-resistant depression, SPRAVATO® may be a more accessible pathway. SPRAVATO® is FDA-approved for treatment-resistant depression and is covered by most major insurance plans for eligible patients — it is our primary recommended option for patients who meet TRD criteria. While SPRAVATO® is not indicated for anxiety as a standalone diagnosis, patients managing both conditions may find that addressing the depressive dimension through an insurance-covered, FDA-approved route opens clinical space that benefits their anxiety as well. Discuss with your provider whether your diagnostic picture makes SPRAVATO® a relevant component of your care.
For eligible veterans, our institute holds a VA Community Care Network (VCA) contract. The VA will refer veterans to us and covers the cost of ketamine infusions through that contract. Veterans managing anxiety alongside service-related conditions should discuss with their provider and VA care coordinator whether the VCA pathway applies to their situation.
We also offer Medication Management services in Minneapolis, which allows our clinical team to assist with the broader psychopharmacological questions that often accompany anxiety treatment — whether a current medication is contributing to treatment resistance, whether anxiolytic medications need adjustment, and how ketamine therapy fits within an overall medication plan. For many anxiety patients, the integration of multiple treatment modalities — medication, psychotherapy, and ketamine — produces outcomes that any single approach alone does not. Results vary by individual, and the goal of our intake process is to create a realistic, personalized plan rather than a standardized template. We encourage every patient to bring their full medication and treatment history to the initial consultation so that we can assess candidacy thoughtfully.
Integration therapy after each session is not optional in our model — it is built in. Anxiety, perhaps more than any other condition, generates meaning in the space between sessions. Insights, behavioral patterns, and somatic awareness that emerge during a ketamine experience need active processing afterward to translate into lasting change. Our team schedules integration appointments as a standard part of the KAP program and adapts the integration content to what specifically arose for each patient during the session.
Frequently Asked Questions
Is ketamine approved for anxiety disorders? No. The use of IV ketamine for anxiety is off-label — not FDA-approved for this indication. Research supporting its use for anxiety is growing but less established than the literature on depression and PTSD. We explain this clearly during every intake consultation. Results vary by individual; discuss with your provider whether ketamine therapy is an appropriate option given your diagnosis and history.
Will the dissociative experience make my anxiety worse? Some patients do find the unfamiliarity of the ketamine experience anxiety-provoking at first, particularly in the first session. Our preparation protocol specifically addresses this concern for anxiety patients, including grounding techniques, detailed explanation of what to expect, and active therapeutic support throughout the session. Many patients report that with adequate preparation, the experience is manageable and even transformative.
Can I continue my current anxiety medication while doing ketamine therapy? This is a clinical question that depends on your specific medications and doses. Some anxiolytic medications may interact with ketamine or blunt its effects; others are compatible. Our Medication Management service and intake evaluation process is designed to assess your current regimen and advise accordingly. Always discuss any medication changes with your prescriber before making them.
How many sessions does it take to see a change in anxiety symptoms? Clinical research suggests some patients report rapid changes within the first one to two sessions; others require the full induction series of six sessions before meaningful shifts occur. Anxiety responses to ketamine tend to be more variable than depression responses, which is why integration work and monitoring across the series are important. Discuss with your provider what a realistic timeline looks like given your clinical history.
What if ketamine doesn’t help my anxiety? Non-response to ketamine does not mean all options are gone. For patients with comorbid treatment-resistant depression, SPRAVATO® may be relevant — it is FDA-approved, covered by most major insurance plans for eligible patients, and is our primary recommended option for those who qualify. Medication Management can identify adjustments to the broader pharmacological regimen. Our team also includes therapists trained in CBT and somatic approaches who can support ongoing care regardless of ketamine response. Results vary by individual.
Key Takeaways
- IV ketamine for anxiety is off-label and not FDA-approved; research is emerging but less established than for depression
- Ketamine’s NMDA receptor mechanism may address the glutamate-GABA dysregulation that underlies many anxiety disorders
- Preparation and integration work are particularly important for anxiety patients to maximize safety and therapeutic benefit
- For patients with comorbid treatment-resistant depression, SPRAVATO® is our primary recommended option — FDA-approved and covered by most major insurance plans for eligible patients
- Veterans referred through the VA Community Care Network (VCA) contract may be eligible to receive ketamine infusions at our institute with VA coverage
- Results vary by individual; a thorough intake evaluation is essential to appropriate candidacy assessment
Anxiety that has not responded to standard treatments deserves a genuinely different clinical option, and ketamine therapy — when delivered with appropriate preparation, expert pharmacological oversight, and skilled integration support — may provide that opening. At Minnesota Ketamine & Wellness Institute, our team brings together the pharmacological precision of advanced practice nursing and the therapeutic depth of specialized trauma and psychedelic therapy training. Schedule a consultation and explore whether ketamine therapy belongs in your treatment plan.
References
Anxiety and Depression Association of America — https://adaa.org/understanding-anxiety
National Institute of Mental Health — https://www.nimh.nih.gov/health/topics/anxiety-disorders
American Psychiatric Association — https://www.psychiatry.org/patients-families/anxiety-disorders
Yale Department of Psychiatry — https://medicine.yale.edu/psychiatry/
About Christy Hatcher, MSN, APRN, CRNA
Christy Hatcher, MSN, APRN, CRNA is the owner and lead provider at Minnesota Ketamine & Wellness Institute. She specializes in ketamine infusions as an alternative or adjunct treatment for depression, anxiety, PTSD, and suicidal ideation. The Institute offers a multidisciplinary team with over 40 years of combined experience in mental health and anesthesia services, including therapists who are Certified Clinical Trauma Professionals, Somatic Psychedelic Facilitators, and licensed clinical social workers certified in psychedelic-assisted therapy. The clinic integrates ketamine-assisted psychotherapy (KAP) and integration therapy alongside infusion services, holds a VA Community Care Network (VCA) contract for eligible veterans, and offers SPRAVATO® as its primary FDA-approved, insurance-covered option for treatment-resistant depression.
Medical Disclaimer
The content of this article is provided by Minnesota Ketamine & Wellness Institute for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Ketamine’s use for anxiety is off-label and not FDA-approved for this indication. Individual results vary. Always discuss treatment options, risks, and benefits with a qualified healthcare provider before making any medical decisions.